Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

3(37.5%)

N/A

1(12.5%)

8Total

Phase 2(4)

Phase 1(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06011798Phase 2Completed

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

Role: lead

NCT05275205Phase 2Completed

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Role: lead

NCT04857996Phase 2Completed

Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)

Role: lead

NCT04537884Phase 1Completed

Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

Role: lead

NCT04129944Phase 2Completed

A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

Role: lead

NCT04349956Terminated

Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

Role: lead

NCT04229225Phase 1Completed

A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee

Role: lead

NCT03513016Phase 1Completed

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

Role: lead

NCT03100799Not ApplicableCompleted

An Exploratory Clinical Study to Investigate Biomarkers of Senescence in Patients With Osteoarthritis of the Knee

Role: lead

All 9 trials loaded